A closely watched next-gen obesity treatment from Novo Nordisk misses the mark in a pivotal trial, results that cast into doubt the future competitiveness of the company in the booming weight loss market.
statnews.com
Next-gen obesity treatment from Novo Nordisk misses mark in pivotal trial
Novo Nordisk’s next-gen obesity drug led patients to lose substantial weight, but fell short of expectations.
